Methods for virus inactivation

Abstract

Various embodiments of the present disclosure relate to systems and methods for adjusting pH in a polypeptide-containing mixture. The pH value can be adjusted for any suitable purpose, such as inactivating viruses in the mixture. The method may include eluting a mixture (e.g., an eluate) having a pH value greater than, for example, 3.9 and less than, for example, 8.5 from a chromatography column. The method may also include one or more of determining a protein concentration of the mixture and determining a pH value of the mixture. The amount of acid necessary to reduce the pH of the mixture to the target pH is then calculated based on the protein concentration of the mixture, the pH of the mixture, or both. After calculating the acid addition amount, a portion of the acid may be added to the mixture, where the portion of the acid is sufficient to achieve the target pH value.

Description

This application is a divisional application of 202080068745.5. CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 881,692, filed on August 1, 2019, the entire disclosure of which is incorporated herein by reference. Technical Field

[0002] The present disclosure generally relates to methods for achieving a target pH value in a mixture containing a polypeptide. More specifically, the present disclosure relates to methods for achieving a target pH value in a mixture containing a polypeptide to help ensure that enveloped viruses or virus-like particles are inactivated. Background Art

[0003] In the production of polypeptides, the target molecule (e.g., the target polypeptide component of a pharmaceutical product) can be separated from the culture medium. A separation process (e.g., affinity chromatography, etc.) can be implemented as part of the target molecule preparation process. After such a separation process, the resulting mixture containing the polypeptide may potentially contain inappropriate viruses or other contaminants that are not suitable for inclusion in the pharmaceutical product. Therefore, methods for removing or inactivating such contaminants are desirable.

[0004] Process Analytical Technology (PAT) may be implemented during some industrial-scale target molecule synthesis processes. PAT includes systems and methods related to the design, analysis, and control of target molecule production processes. PAT includes the determination of process parameters that affect product quality and the regular monitoring of these parameters to ensure that product quality is maintained. PAT is encouraged by regulatory authorities to reduce risks associated with target molecules and drug products in general. PAT can provide statistical verification or confirmation that one or more process conditions that can improve or maintain the quality of the target molecule and / or product are met.

[0005] The methods and systems disclosed herein can improve the efficiency and / or productivity of polypeptide preparation methods including virus inactivation. The methods and systems disclosed herein can also improve the efficiency and / or productivity of pharmaceutical product preparation methods, and can solve one or more of the above-mentioned problems. Summary of the invention

[0006] Various embodiments of the present disclosure may relate to a method for inactivating viruses in a mixture (e.g., an eluent). The method may include eluting a mixture at a pH greater than 3.9 and less than 8.5 from a chromatography column. The method may also include determining the protein concentration of the mixture and determining the pH value of the mixture. Then, based on the protein concentration of the mixture, the amount of acid necessary to reduce the pH value of the mixture to the inactivation pH value may be calculated. After calculating the amount of acid added, the acid of the first part may be added to the mixture, wherein the acid of the first part is 68% to 99% of the amount of acid added. The method may also include adding another portion of the acid to the mixture so that the pH value of the mixture is at or below the inactivation pH value. In the method of the present disclosure, the mixture may be maintained at the inactivation pH value for an inactivation period of time for inactivating viruses in the mixture.

[0007] In some embodiments of the present disclosure, the method for inactivating the virus in the mixture may include loading the mixture containing the target molecule into a chromatography column, the loading occurring at a pH value greater than or equal to about 5.0 and less than or equal to about 8.5. The method may also include eluting from the chromatography column at a pH value greater than about 3.9 and less than or equal to about 5.0, the eluted mixture containing the target molecule. The method also includes adding an acid to the mixture to form a composition of the mixture and the acid, wherein the composition is for showing effective virus inactivation and the composition has a pH value less than or equal to about 3.8 and greater than or equal to about 3.0. The expected pH value of the composition can be predetermined using a pH confirmation model. In addition, the pH value of the composition can be measured and / or recorded. The difference between the expected pH value and the recorded pH value can be calculated, and corrective measures can be taken based on the calculated difference between the expected pH value and the recorded pH value.

[0008] Other embodiments of the present disclosure may include a method for establishing an acid inactivation protocol. The method may include making a pool of eluates, wherein each eluate of the eluate pool contains a target molecule that is purified during protein affinity capture. The method may include determining the pH value and / or protein concentration of each eluate of the eluate pool. In addition, each eluate of the eluate pool may be titrated to determine the amount of acid required to bring the eluate to an inactivation pH. Then, the relationship between the amount of acid added, the eluate protein concentration, the eluate pH, and the inactivation pH may be regressed.

[0009] In some embodiments of the present disclosure, a method for inactivating a virus in a mixture may include determining the protein concentration of the mixture. Then, based on the protein concentration of the mixture, the amount of acid necessary to reduce the pH of the mixture to the inactivation pH value may be calculated. After calculating the amount of acid to be added, the amount of acid necessary to reduce the pH of the mixture may be added to the mixture. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] The accompanying drawings, which are incorporated into and form a part of this specification, illustrate various exemplary embodiments and are used to explain the principles of the disclosed embodiments together with the description. Any features (e.g., composition, dosage form, method, etc.) of the embodiments or embodiments described herein may be combined with any other embodiment or embodiment, and all such compositions are included in the present disclosure. In addition, the described systems and methods are neither limited to any single aspect or its embodiment nor to any composition or arrangement of the above aspects and embodiments. For the sake of brevity, certain arrangements and compositions are not discussed and / or described separately herein.

[0011] Figure 1 An exemplary process for inactivating viruses in an eluate (eluate) according to the present disclosure is depicted in the form of a flow chart;

[0012] Figure 2 An exemplary process for inactivating viruses in an eluate according to the present disclosure is depicted in the form of a flow chart; and

[0013] Figure 3 An exemplary process for establishing an acid inactivation protocol according to the present disclosure is depicted in flow chart form.

[0014] As used herein, the words "include," "comprising," or any other variation thereof are intended to encompass a non-exclusive inclusion, whereby a process, method, article, or apparatus that includes a list of elements includes not only those elements, but may also include other elements not expressly listed or peculiar to such process, method, article, or apparatus. The term "exemplary" is used in the sense of "example" rather than "ideal." With respect to the words "for example" and "such as," and their grammatical equivalents, they should be understood to follow the phrase "and without limitation," unless expressly stated otherwise.

[0015] As used herein, the word "about" is intended to account for variations due to experimental error. When applied to numerical values, the words "about" and "approximately" may include variations of + / -5% relative to the disclosed numerical values ​​unless a different variation is specified. When applied to pH values, the terms "about" and "approximately" may include variations of + / -0.05. As used herein, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise.

[0016] It should be noted that all numerical values ​​disclosed herein (including all disclosed values, limits, and ranges) may have a variation of + / -5% relative to the disclosed numerical values, unless a different variation is specified. The pH values ​​disclosed herein may have a variation of + / -0.05. In addition, all ranges are understood to include endpoints, for example, 1 centimeter (cm) to 5 cm will include a length of 1 cm, 5 cm, and all distances between 1 cm and 5 cm. DETAILED DESCRIPTION

[0017] The present disclosure is not limited to specific compositions, dosage forms, material manufacturers, drug products, devices, systems, experimental conditions, or specific methods disclosed herein, as many variations are possible within the purview of those skilled in the art. The terminology used herein is for the purpose of describing specific embodiments only and is not intended to be limiting.

[0018] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the present disclosure belongs. Although any suitable methods and materials (e.g., similar to or equivalent to those described herein) may be used for the implementation or testing of the present disclosure, specific methods are now described. All publications mentioned are incorporated herein by reference.

[0019] As used herein, the term "polypeptide" refers to any amino acid polymer having more than about 20 amino acids covalently linked via amide bonds. Proteins contain one or more amino acid polymer chains (e.g., polypeptides). Thus, a polypeptide can be a protein, and a protein can contain multiple polypeptides to form a single functional biomolecule.

[0020] Post-translational modifications can modify or change the structure of a polypeptide. For example, in some proteins, disulfide bonds (e.g., SS bonds between cysteine ​​residues) can be formed after translation. Some disulfide bonds are essential for the proper structure, function, and interaction of polypeptides, immunoglobulins, proteins, cofactors, substrates, etc. In addition to disulfide bond formation, proteins can undergo other post-translational modifications, such as lipidation (e.g., myristoylation, palmitoylation, farnesylation, geranylgeranylation, and glycosylphosphatidylinositol (GPI) anchor formation), alkylation (e.g., methylation), acylation, amidation, glycosylation (e.g., addition of glycosyl groups at arginine, asparagine, cysteine, hydroxylysine, serine, threonine, tyrosine, and / or tryptophan), and phosphorylation (i.e., adding a phosphate group to serine, threonine, tyrosine, and / or histidine). Post-translational modifications can affect hydrophobicity, electrostatic surface properties, or other properties that determine the surface-surface interactions in which the polypeptide participates.

[0021] As used herein, the term "protein" includes biotherapeutic proteins, recombinant proteins for research or treatment, trap proteins and other Fc-fusion proteins, chimeric proteins, antibodies, monoclonal antibodies, human antibodies, bispecific antibodies, antibody fragments, antibody-like molecules, nanobodies, recombinant antibody chimeras, cytokines, chemokines, peptide hormones, etc. Proteins of interest (POI) may include any polypeptide or protein that is desired to be isolated, purified, or prepared. POI may include target polypeptides or other polypeptides (including antibodies) produced by cells.

[0022] The term "antibody" as used herein includes immunoglobulins consisting of four polypeptide chains (two heavy (H) chains and two light (L) chains) interconnected by disulfide bonds. Typically, antibodies have a molecular weight of more than 100 KDa, such as between 130 KDa and 200 KDa, such as about 140 KDa, 145 KDa, 150 KDa, 155 KDa, or 160 KDa. Each heavy chain includes a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region includes three domains: CH1, CH2 and CH3. Each light chain includes a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region includes a domain CL. The VH region and VL can be further subdivided into hypermutated regions (referred to as complementary determining regions (CDRs)) interspersed with more conserved regions (referred to as framework regions (FRs)). Each VH and VL is composed of three CDRs and four FRs arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (the heavy chain CDR can be abbreviated as HCDR1, HCDR2 and HCDR3; the light chain CDR can be abbreviated as LCDR1, LCDR2 and LCDR3).

[0023] For example, a class of immunoglobulins known as immunoglobulin G (IgG) is common in human serum and includes four polypeptide chains (two light chains and two heavy chains). Each light chain is connected to a heavy chain by a cystine disulfide bond, and the two heavy chains are bound to each other via two cystine disulfide bonds. Other types of human immunoglobulins include IgA, IgM, IgD, and IgE. In the case of IgG, there are four subclasses: IgG1, IgG2, IgG3, and IgG4. Each subclass is different in their constant region and therefore may have different effects or functions. In some embodiments described herein, the POI may include a target polypeptide (which includes IgG). In at least one embodiment, the target polypeptide includes IgG4.

[0024] The term "antibody" as used herein also includes antigen-binding fragments of complete antibody molecules. As used herein, the term "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, etc., includes any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of an antibody can be obtained from a complete antibody molecule, for example, using any suitable standard techniques (such as protease cleavage) or recombinant genetic engineering techniques including the manipulation and expression of DNA-encoded antibody variable domains and optionally constant domains. Such DNA is known and / or can be easily obtained from, for example, commercial sources, DNA libraries (including, for example, phage-antibody libraries), or can be synthesized. DNA can be sequenced and manipulated using chemical methods or using molecular biological techniques, for example, to arrange one or more variable and / or constant domains into a suitable configuration, or to introduce codons, form cysteine ​​residues, modify, add or delete amino acids, etc.

[0025] The target molecule (e.g., target polypeptide) can be produced using a recombinant cell-based production system such as an insect baculovirus system, a yeast system (e.g., Pichia pastoris), or a mammalian system (e.g., CHO cells and CHO derivatives such as CHO-K1 cells). The term "cell" includes any cell suitable for expressing a recombinant nucleic acid sequence. Cells include prokaryotic and eukaryotic cells (single or multicellular), bacterial cells (e.g., strains of Escherichia coli, Bacillus, Streptomyces, etc.), mycobacterial cells, fungal cells, yeast cells (e.g., Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, Pichia methanolica, etc.), plant cells, insect cells (e.g., SF-9, SF-21, baculovirus-infected insect cells, Trichoplusia ni, etc.), non-human animal cells, human cells, or cell fusions (e.g., hybridomas or quadromas). In some embodiments, the cell can be a human, monkey, ape, hamster, rat, or mouse cell. In some embodiments, the cell can be a eukaryotic cell and can be selected from the following cells: CHO (e.g., CHOK1, DXB-11 CHO, Veggie-CHO), COS (e.g., COS-7), retinal cells, African green monkey kidney cells, CV1, kidney cells (e.g., HEK293, 293EBNA, MSR293, MDCK, HaK, BHK), HeLa cells (HeLa), HepG2, WI38, MRC5, Colo205, HB8065, HL-60 (e.g., BHK21), Jurkat cells, Daudi cells, A431 (epidermal), CV-1, U937, 3T3, L cells, C127 cells, SP2 / 0, NS-0, MMT060562, Sertoli cells, BRL3A cells, HT1080 cells, myeloma cells, tumor cells, and cell lines derived from the foregoing cells. In some embodiments, the cells may contain one or more viral genes, such as retinal cells expressing viral genes (e.g., PER.C6 TM cell).

[0026] The term "target molecule" herein may be used to refer to a target polypeptide (e.g., an antibody, an antibody fragment, or other protein or protein fragment), or to other molecules that are intended to be produced, isolated, purified, and / or included in a pharmaceutical product (e.g., an adeno-associated virus (AAV) or other molecules for therapeutic use). Although the methods according to the present disclosure may be applicable to target polypeptides, they may also be applicable to other target molecules. For example, an adeno-associated virus may be prepared according to a suitable method (e.g., deep filtration, affinity chromatography, etc.), and a mixture containing an adeno-associated virus (e.g., an eluate containing an adeno-associated virus) may be subjected to a method according to the present disclosure. Before or after using one or more methods of the present disclosure, the mixture containing an adeno-associated virus may undergo additional steps (e.g., removal of an "empty box" or an adeno-associated virus that does not contain a target sequence).

[0027] The term "viral content" refers to a qualitative description of a mixture. For example, if a mixture contains viruses or virus-like particles, the mixture has a viral content. In some embodiments, the viral content can be quantified by the number of viral particles or the number of infectious units per volume of the mixture (i.e., concentration). The term "viral concentration" can refer to the concentration of viral particles (e.g., active and inactive viral particles) or the concentration of infectious units.

[0028] Exemplary methods for viral inactivation may include adding an acid to a mixture to achieve a pH known to inactivate some viruses and virus-like particles, and maintaining the mixture at a pH of 10 for a predetermined amount of time. For example, in some embodiments, the methods herein may inactivate retroviruses and retrovirus-like particles. In some embodiments, a method for preparing a target molecule from a mixture comprising a target molecule may include contacting the mixture with a chromatographic device. Such a chromatographic device may include a prefabricated device (e.g., Cadence TM BioSMB (Pall Biosciences), (Nnovasep), (Novasep), or Octave( Biosciences), custom devices, hand-assembled devices, or simply using two or more standard batch chromatography devices in series.

[0029] In some embodiments, the target molecule can be eluted from the chromatography device by contacting a stripping buffer with the chromatography device (e.g., a chromatography column) and / or contacting an equilibration buffer with the chromatography device. In some embodiments, the stripping buffer can include water, an alkaline solution, or a solution containing an alcohol. The water (e.g., deionized water) can, for example, have less than 5 volume percent (volume %) dissolved ions, less than 1 volume % dissolved ions, less than 0.1 volume % dissolved ions, or even less than 0.01 volume % dissolved ions. According to some embodiments, the alkaline solution can include one or more alkaline ionic compounds, such as LiOH, NaOH, KOH, Ca(OH) 2 NH 4 OH or other alkaline compounds. The concentration of the alkaline compound in the stripping buffer may be, for example, in the range of about 0.1N to about 1.5N, about 0.1N to about 1N, about 0.1N to about 1.5N, about 0.5N to about 1.5N, about 0.1N to about 0.8N, about 0.1N to about 0.6N, about 0.1N to about 0.5N, about 0.1N to about 0.4N, or about 0.1N to about 0.3N. For example, the concentration of the alkaline compound in the stripping buffer may be about 0.1N, about 0.2N, about 0.3N, about 0.4N, about 0.5N, about 0.6N, about 0.7N, about 0.8N, about 0.9N, about 1N, about 1.1N, about 1.2N, about 1.3N, about 1.4N, or about 1.5N. The stripping buffer containing alcohol may include methanol, ethanol, propanol, benzyl alcohol, or other alcohols. Based on the total weight of the stripping buffer, the concentration of alcohol in the stripping buffer may be in the range of about 0.1 volume % to about 30 volume %, such as about 0.5 volume % to about 30 volume %, about 0.5 volume % to about 25 volume %, about 0.5 volume % to about 25 volume %. About 0.5 volume % to about 25 volume %, about 1 volume % to about 20 volume %, about 1 volume % to about 15 volume %, about 1 volume % to about 10 volume %, about 10 volume % to about 50 volume %, about 10 volume % to about 40 volume %, about 10 volume % to about 30 volume %, about 10 volume % to about 25 volume %, about 15 volume % to about 25 volume %, or about 20 volume % to about 25 volume %. For example, the concentration of alcohol in the stripping buffer may be about 0.1 volume %, about 0.5 volume %, about 1 volume %, about 2 volume %, about 3 volume %, about 5 volume %, about 10 volume %, about 15 volume %, about 20 volume %, or about 25 volume %.

[0030] In some embodiments, the composition of the equilibration buffer may be similar or identical to the stripping buffer. In other embodiments, the equilibration buffer composition may vary compared to the stripping buffer. In some embodiments, the equilibration buffer may comprise one or more salts, such as sodium salts, potassium salts, magnesium salts, calcium salts, citrates, acetates, phosphates, sulfates, tris, or other salts.

[0031] In one or more embodiments, a mixture containing a target molecule can be eluted from a chromatographic device (e.g., a packed bed affinity chromatography column, a hydrophobic interaction chromatography column, an ion exchange chromatography column, and / or a size exclusion chromatography column) after being used for a method of inactivating the virus. The target molecule is loaded into the chromatographic device and can be varied based on the upstream process, and the mixture containing the target molecule can be eluted from the chromatographic device at a constant volume. In some embodiments, the mixture containing the target molecule is loaded on the chromatographic column at a pH of greater than or equal to about 5.0 and less than or equal to about 8.5, for example, greater than or equal to about 5.5 and less than or equal to about 8.5, greater than or equal to about 6.0 and less than or equal to about 8.5, or about 5.0 to about 6.5. Due to changes in loading, the protein concentration and / or pH value in the eluate (e.g., the eluate eluted from the chromatographic device) can vary. Due to this change, the amount of acid required for viral inactivation is also changed.

[0032] In conventional production processes, low pH virus inactivation is accomplished using a trial and error methodology, where a predetermined amount of acid is added to the eluate, the pH of the eluate and acid mixture is measured, and the addition and measurement steps are repeated until the inactivation pH is reached. Due to the potential costs and losses associated with excessive acid addition, this process is conservative and involves small acid additions and long inactivation process times (often on the scale of hours).

[0033] Aspects of the present disclosure can provide various benefits to the process of preparing target polypeptide or other target molecule. For example, one or more methods and / or mathematical models described herein can be implemented to determine the acid addition, for example, to make the mixture (containing the target molecule and potentially unwanted virus or virus-like particles) reach the amount of acid required for the inactivation pH value. The acid of the amount roughly equivalent to the acid addition can be added to the mixture. As described in more detail below, the acid amount suitable for the acid addition can be added with a single or two or more acid applications. Compared with traditional trial and error, administering drugs in this way for viral inactivation may be more effective and less prone to error.

[0034] In some aspects of the disclosure, as part of the process, the viral content or infectious unit content in the mixture may be known or expected to be minimal or absent. In some such aspects of the disclosure, the systems and methods disclosed herein may be advantageously incorporated into a production process as part of a process analytical technology to, for example, reduce potential variability within the process, provide real-time confirmation of compliance with process standards, and / or improve confidence in process integrity.

[0035] Other benefits and advantages of various aspects of the present disclosure will be apparent to those skilled in the art.

[0036] As previously described, after preparing the target molecule using one or more chromatography and / or separation processes, a mixture (e.g., an eluate) can be obtained. In some embodiments, the mixture can be subjected to one or more measurements, including, for example, protein concentration, target molecule concentration, pH, or a combination thereof. The protein concentration can be determined by any suitable method (including, for example, using UV / visible spectroscopy). In some embodiments, the protein concentration is determined using a wavelength characteristically absorbed by the target molecule (which can be a polypeptide). In such embodiments, the total protein concentration can be approximately equal to the concentration of the target molecule (e.g., target polypeptide). In some embodiments, the mixture comprising the target molecule can have a concentration of approximately 7.0 grams of protein per liter of eluate (g / L ) to about 35.0g / L , greater than or equal to 7.0g / L , less than or equal to about 20.0g / L , about 8.5g / L To about 18.5g / L , or about 10.0g / L To about 17.0g / L of protein concentration.

[0037] The pH value of the mixture can be determined by any suitable method. Accurate and consistent pH determination is important for the successful inactivation of viral proteins by low pH. The determination of pH value will be affected by temperature, the type of pH probe used, individual differences between the same type of pH probes, and / or the physical interaction between the determination medium and the pH probe. Even in the standardized pH determination process, changes of ± 0.05 pH will be common. In the field of polypeptide production or virus inactivation, changes in the scale of ± 0.05 pH can be equivalent to about 20% of the working pH range and will adversely affect virus inactivation and / or process validation. This change will even be compounded over time, resulting in instrument drift and more extreme changes in pH determination. Therefore, in some embodiments, when determining pH, changes in pH determination will be considered. In some embodiments, as described above, the pH value of the eluate is determined by a standardized method, and the purpose is to reduce or eliminate variability in pH determination. The standardization of pH determination methods can include: using a pH probe from a single manufacturer, using a single batch of pH probes, determining pH at a predetermined temperature, standardizing the determination sample matrix, etc. In some embodiments, the pH value of the eluate can be measured using a pH meter (e.g., a potentiometric pH meter). In some embodiments, the eluate comprising the target molecule can have a pH value greater than or equal to about 3.9 and less than or equal to about 8.5, such as about 3.9 to about 6.5, about 3.9 to about 5.5, about 4.5 to about 6.5, about 4.0 to about 4.4, about 3.9 to about 4.4. Or about 4.0 to about 4.3. As used herein, the pH value or the range of pH values ​​can have a change of ± 0.05 pH units.

[0038] The presence of some viruses and virus-like particles (e.g., enveloped viruses, retroviruses, retrovirus-like particles, pseudorabies virus, herpes virus, etc.) in a mixture (e.g., eluate), formulation, and / or drug product may affect the composition, properties, or usability of such mixture, formulation, and / or drug product. For example, the presence of unwanted viruses or virus-like particles in a drug product may affect product stability, reduce the shelf life of the product, or cause the product to fail to meet internal, pharmacopoeial, or regulatory (e.g., U.S. Food and Drug Administration) specifications. When administering a drug product containing a virus, some viruses or virus-like particles may cause clinical effects (e.g., immunogenic reactions). The various embodiments of the present disclosure may be used to inactivate viruses or virus-like particles to reduce or eliminate any or all adverse effects. For example, the various embodiments of the present disclosure may be applicable to a mixture (e.g., eluate) having a viral content after one or more polypeptide purification processes (e.g., a separation process including a protein A affinity column).

[0039] In some embodiments, before the virus is inactivated, the conductivity of the mixture can be determined. In some embodiments, before the virus is inactivated, one or more salts can be added to the mixture to adjust its conductivity (e.g., to increase the conductivity). The one or more salts can include alkali metal salts, alkaline earth metal salts, halides, and / or one or more other ion-active compounds. Without being limited by theory, adding one or more salts to adjust the conductivity can reduce the aggregation of target molecules, viruses, or retrovirus-like particles. The aggregation of target molecules, viruses, or retrovirus-like particles can affect how much surface these substances have to interact with the acid. Adding salt to the mixture can increase the ionic activity of the mixture, increase the conductivity of the mixture, and reduce the aggregation of target molecules or viruses. Therefore, in some embodiments, the conductivity of the mixture can be related to the degree of aggregation of the target molecules or viruses.

[0040] In some cases, each embodiment of the present disclosure may be applicable to mixtures with extremely low viral content (e.g., less than or equal to about 0.0001 viral particles or infection units / mL), or even no viral content. Chromatography and other separation processes (alone or in combination) can fully purify and / or separate target molecules from the mixture and remove unwanted viruses or virus-like particles. In some such cases, methods according to the present disclosure may be helpful to further ensure that viruses or virus-like particles are inactivated, as well as ensure product stability, product safety, product effectiveness, and compliance with internal or management specifications. Therefore, each embodiment of the present disclosure may also be applicable to mixtures without any known viral content, so as to, for example, ensure that management criteria are met and / or provide redundant quality control.

[0041] The virus inactivation protocols and methods described herein can be implemented without negatively affecting certain types of viruses, such as adeno-associated viruses (e.g., adeno-associated viruses containing target sequences). For example, advantageously, the protocols and methods described herein can be implemented without degrading adeno-associated viruses. Thus, the methods described herein can be applied to mixtures containing adeno-associated viruses (AAVs) as target molecules.

[0042] As mentioned above, the viruses in the mixture can be inactivated by maintaining the mixture at an inactivation pH value for an inactivation period of time. The inactivation pH value can be less than or equal to 3.8 and greater than or equal to 3.0, such as 3.35 to 3.8, less than or equal to 3.75 and greater than or equal to 3.0, less than or equal to 3.7 and greater than or equal to 3.0, less than or equal to 3.65 and greater than or equal to 3.0, less than or equal to 3.6 and greater than or equal to 3.0, less than or equal to 3.55 and greater than or equal to 3.0, less than or equal to 3.5 and greater than or equal to 3.0, less than or equal to 3.45 and greater than or equal to 3.0, less than or equal to 3.4 and greater than or equal to 3.0, 3.35 to 3.75, 3.5 to 3.8, 3.5 to 3.75, 3.5 to 3.7, 3.5 to 3.6, or 3.5 to 3.65. As used herein, a pH value or range of pH values ​​may have a variation of ±0.05 pH units. If the inactivation pH is set too high, there is a risk of variations in the process that may result in insufficient viral inactivation. If the inactivation pH is set too low, there is a risk of denaturing the target molecule or other proteinaceous species, or altering the mixture in an inappropriate manner.

[0043] Inactivation time period represents the time period during which mixture is maintained at the inactivation pH value.The inactivation time period can be about 20 minutes to about 90 minutes, for example, about 30 minutes, about 45 minutes, about 60 minutes, about 30 minutes to about 45 minutes, about 30 minutes to about 60 minutes, about 30 minutes to about 75 minutes, about 30 minutes to about 90 minutes, about 45 minutes to about 60 minutes, about 45 minutes to about 75 minutes, about 45 minutes to about 90 minutes, about 60 minutes to about 75 minutes, or about 60 minutes to about 95 minutes.The mixture is maintained at the inactivation pH value and reaches the inactivation time period and can reduce, eliminate the viral activity in the mixture or ensure that it does not exist.Low pH environment can make viral protein (for example, viral envelope protein) denaturation.Degenerated viral protein can make retrovirus and retrovirus-like particles inactive, thereby reducing the unwanted viral activity of mixture.

[0044] The reduction in viral activity in the mixture can be quantified using the reduction factor. The reduction factor can be calculated according to Equation 1 shown below: Reduction Factor: Reduction factor Where V 1 is the volume of the mixture before virus inactivation, C 1 is the virus concentration or infectious unit per volume of the mixture before virus inactivation, V 2 is the volume of the mixture after virus inactivation, and C 2is the virus concentration of the mixture after virus inactivation. In various embodiments of the present disclosure including methods for virus inactivation, a reduction factor of greater than or equal to 2.5 is obtained, for example, a reduction factor of greater than or equal to 3, greater than or equal to 3.5, greater than or equal to 4, greater than or equal to 4.5, or greater than or equal to 5. As used herein, "effective virus inactivation" may refer to virus inactivation associated with a reduction factor of greater than or equal to 2.5, greater than or equal to 3, greater than or equal to 3.5, greater than or equal to 4, greater than or equal to 4.5, or greater than or equal to 5.

[0045] According to one or more embodiments, the amount of acid to be added can be calculated based on the protein concentration of the mixture and the inactivation pH value. For example, the amount of acid to be added can be calculated according to Equation 2 shown below: w=Ax+By+C Equation (2) Where x is the protein concentration of the mixture in grams per liter (g / L), y is the inactivation pH, w is the amount of acid added in moles of acid per kilogram of mixture (mol / kg), and A, B, and C are constants. The constant A of Equation 2 has units of liters·moles of acid per gram kilogram of mixture (L·mol / g·kg). The constant A may be greater than or equal to 0.0003 L·mol / g·kg and less than or equal to 0.0006 L·mol / g·kg, for example, from about 0.0003 L·mol / g·kg to about 0.0005 L·mol / g·kg, from about 0.0004 L·mol / g·kg to about 0.0006 L·mol / g·kg, from about 0.00035 L·mol / g·kg to about 0.0005 L·mol / g·kg, from about 0.00035 L·mol / g·kg to about 0.0006 L·mol / g·kg, or from about 0.0004 L·mol / g·kg to about 0.00055 L·mol / g·kg. The constants B and C of Equation 2 have the unit of moles of acid per kilogram of mixture (mol / kg). The constant B may be greater than or equal to -0.1 mol / kg and less than or equal to 0 mol / kg, for example, from about -0.1 mol / kg to about 0 mol / kg, from about -0.1 mol / kg to about -0.05 mol / kg, from about -0.05 mol / kg to about 0 mol / kg, or from about -0.08 mol / kg to about -0.01 mol / kg. The constant C may be greater than or equal to 0.02 mol / kg and less than or equal to 0.1 mol / kg, for example, from about 0.02 mol / kg to about 0.1 mol / kg, from about 0.02 mol / kg to about 0.05 mol / kg, from about 0.05 mol / kg to about 0.1 mol / kg, or from about 0.04 mol / kg to about 0.08 mol / kg.

[0046] In some embodiments, the amount of acid added can be calculated based on the protein concentration of the mixture, the inactivation pH value, and the pH of the mixture. For example, the amount of acid added can be calculated according to Equation 3 shown below, w=Ex+Fy+Gz+H Equation (3) Wherein x is the mixture protein concentration in grams per liter (g / L), y is the inactivation pH, z is the mixture pH, w is the amount of acid added in moles of acid per kilogram of mixture (mol / kg), and E, F, G, and H are constants. The constant E of Equation 3 has units of liters·moles of acid per gram·kilogram of mixture (L·mol / g·kg) and the constants F, G, and H have units of moles of acid per kilogram of mixture (mol / kg). The constant E may be greater than or equal to 0.00005 L·mol / g·kg and less than or equal to 0.0005 L·mol l / g·kg, for example, about 0.00005L·mol / g·kg to about 0.0005L·mol / g·kg, about 0.0001L·mol / g·kg to 0.0005L·mol / g·kg, about 0.00005L·mol / g·kg to 0.00045L·mol / g·kg, about 0.0001L·mol / g·kg to about 0.00035L·mol / g·kg, or about 0.00035L·mol / g·kg to about 0.0005L·mol / g·kg. The constant F can be large The constant G may be greater than or equal to -0.2 mol / kg and less than or equal to 0 mol / kg, for example, about -0.1 mol / kg to about 0 mol / kg, about -0.1 mol / kg to about -0.05 mol / kg, about -0.05 mol / kg to about 0 mol / kg, or about -0.08 mol / kg to about -0.01 mol / kg. The constant G may be greater than or equal to 0 mol / kg and less than or equal to 0.03 mol / kg, for example, about 0 mol / kg to about 0.03 mol / kg, about 0.001 mol / kg to about 0.0 The constant H may be a number greater than or equal to -0.1 mol / kg and less than or equal to 0.1 mol / kg, such as about -0.1 mol / kg to about 0.1 mol / kg, about -0.08 mol / kg to about 0.08 mol / kg, about -0.05 mol / kg to about 0.1 mol / kg, or about -0.1 mol / kg to about 0.05 mol / kg.

[0047] This particular equation that relates the mixture protein concentration to the amount of acid added and the inactivation pH (which may optionally depend on the mixture pH) may vary with the target molecule and / or the acid system used. The values ​​of the constants defined above, applied to a given target molecule and acid system, may be determined by regression according to the general equation defined above. As described in the Examples section below, it was unexpectedly found that the amount of acid added had a strong correlation with the mixture protein concentration according to the equation defined above. This unexpectedly strong correlation may allow the general equations described herein and their derivatives to be incorporated into process analytical technology (PAT).

[0048] In one or more embodiments, the acid is added in an amount of about 0.002 moles of acid per kilogram of mixture (mol / kg) to about 0.025 mol / kg, for example, about 0.002 mol / kg to about 0.025 mol / kg, about 0.01 mol / kg to about 0.025 mol / kg, about 0.002 mol / kg to about 0.020 mol / kg, or about 0.005 mol / kg to about 0.020 mol / kg.

[0049] In some embodiments, after calculating the amount of acid added, the acid can be added to the mixture so that the mixture is at an inactivation pH. For example, in at least one embodiment, a dose of acid (equal to the amount of acid added) can be added to the mixture so that the pH of the mixture is less than or equal to the inactivation pH. In other embodiments, a first portion of the acid is added to the mixture, and then one or more additional portions of the acid can be added to the mixture so that the pH of the mixture is at or below the inactivation pH. In such embodiments, the first portion of the acid is 68% to 99% of the amount of acid added, for example, about 75% to about 99%, about 80% to about 99%, about 85% to about 99%, about 90% to about 99%, about 85% to about 95%, or about 90% to about 99%.

[0050] The ratio of the acid of the first part can be determined so that the target molecule in the mixture with the lowest possible pH value will not be denatured by the addition of the first part of the acid. The acid of the other part can include one or more additions of the acid that occur after the addition of the first part of the acid, such as 3 acid additions, 4 acid additions, or 5 acid additions that are carried out after the addition of the first part of the acid. Each addition of the one or more acid additions can be 0.1% to 32% of the acid addition, such as about 0.1% to about 30%, about 0.1% to about 25%, about 0.1% to about 20%, about 1% to about 25%, about 0.1% to about 15%, about 0.1% to about 10%, about 1% to about 15%, about 1% to about 10%, or about 0.1% to about 5%. Each addition of the one or more acid additions can be added in the same amount as one or more other acids. In other embodiments, each acid addition is added in the same amount as each other acid addition.

[0051] In some embodiments, the pH value can be measured after the first portion of the acid is added to the mixture but before the additional portion of the acid is added. In some such embodiments, the pH value of the mixture, measured after the first portion of the acid is added, is greater than or equal to 3.5 and less than or equal to 3.75, such as about 3.5 to about 3.75, about 3.6 to about 3.7, about 3.5 to about 3.65, about 3.6 to about 3.75, or about 3.5 to about 3.65. As used herein, the pH value or range of pH values ​​can have a variation of ± 0.02 pH units.

[0052] The acid may be added in the form of one or more acidic solutions. The acidic solution may include any suitable acid, such as HCl, HBr, H 3 PO 4 , HO 2 C 2 O 2 H.C 6 H 8 O 7 , H 2 SO 3 , H 3 PO 4 , HNO 2 , C 6 H 5 CO 2 H, CH 3 CO 2 H, HClO, HCN, H 3 BO 3 , or a combination thereof. Additionally or alternatively, the acidic solution may comprise one or more salts, such as glycine, arginine, sodium acetate, and / or sodium chloride.

[0053] After the acid addition amount is added to the mixture containing the target molecule, the formed mixture has a pH value at or below the inactivation pH value. In some embodiments, the pH value of the formed mixture can be determined, for example, to confirm that it is within the desired range. As previously described, the mixture can be maintained at the inactivation pH value for the inactivation time period. After the mixture is maintained at the inactivation pH value for the inactivation time period, the reduction in viral activity can occur with a reduction factor equal to, for example, greater than or equal to 2.5, greater than or equal to 3, greater than or equal to 3.5, or greater than or equal to 4. After the mixture is maintained at the inactivation pH for the inactivation period of time, the mixture can be titrated (dripped) by adding an alkaline solution so that the pH of the mixture is greater than or equal to 4.5 and less than or equal to 8.5, such as greater than or equal to 4.5 and less than or equal to 8.5, greater than or equal to 5.0 and less than or equal to 8.5, greater than or equal to 5.8 and less than or equal to 8.5, greater than or equal to 5.9 and less than or equal to 8.5, greater than or equal to 6.0 and less than or equal to 8.5, greater than or equal to 6.1 and less than or equal to 8.5, greater than or equal to 6.2 and less than or equal to 8.5, greater than or equal to 6.3 and less than or equal to 8.5, or greater than or equal to 6.4 and less than or equal to 8.5. As used herein, the pH value or range of pH values ​​may have a variation of ±0.02 pH units. The alkaline solution may include one or more bases, such as NaOH, KOH, LiOH, Ca(OH) 2 NH 4 OH, NaCH 3 CO 2 and / or (HOCH 2 ) 3 CNH 2 .

[0054] In some embodiments, after adding the first portion of the acid, the mixture is titrated (dripped) for less than 1 hour, such as less than about 50 minutes, less than about 45 minutes, less than about 40 minutes, less than about 35 minutes, or less than about 30 minutes.

[0055] Aspects of the present disclosure may also include methods for determining a function prediction of the pH of a composition (i.e., a combined mixture and acid). For example, a function can be determined that predicts the pH of a composition (e.g., an inactivation pH) based on the measured protein concentration and / or pH of the mixture, and an amount of acid is added to the mixture. Such a function can be used to detect processing errors (e.g., insufficient mixing, poor sampling, etc.) or defects in equipment (instrument errors, instrument drift, pH probe malfunction, etc.).

[0056] In some embodiments, the expected pH of the acidified mixture is predetermined based on a validation model. The validation model may take the form of Equation 4 shown below: y=Kx+Lw+Mz+NEquation (4) Wherein y is the inactivation pH, x is the protein concentration of the mixture in g / L, z is the pH of the mixture, w is the amount of acid added in moles of acid per kilogram of the mixture (mol / kg), and K, L, M, and N are constants. The constant K of Equation 4 has units of liters per gram, the constant L has units of kilograms of the mixture per mole of acid, and the constants M and N are unitless. The constant K may be greater than or equal to 0 L / g and less than or equal to 0.03 L / g, for example, from about 0 L / g to about 0.03 L / g, from about 0.001 L / g to about 0.03 L / g, from about 0 L / g to about 0.025 L / g, or from about 0.001 L / g to about 0.025 L / g. 5L / g. The constant L may be greater than or equal to -80kg / mol and less than or equal to -60kg / mol, for example, from about -75kg / mol to about -60kg / mol, from about -80kg / mol to about -65kg / mol, or from about -75kg / mol to about -65kg / mol. The constant M may be greater than or equal to 0 and less than or equal to 2.0, for example, from about 0 to about 2.0, from about 0.3 to about 2.0, from about 0 to about 1.7, or from about 0.3 to about 1.7. The constant N may be greater than or equal to -1.0 and less than or equal to 0, for example, from about -1.0 to about 0, from about -1.0 to about -0.1, or from about -0.9 to about -0.1.

[0057] In some embodiments, the pH value and protein concentration of the mixture can be measured and / or recorded before acid is added. Based on the mixture pH value, the protein concentration of the mixture and the amount of acid added, the expected pH value of the acidified mixture can be predetermined using a validation model. The actual pH value of the acidified mixture can be measured, recorded, and / or compared with the expected pH value. The comparison of the recorded pH value with the expected pH value can include calculating the difference (e.g., percentage difference) between the recorded pH value and the expected pH value.

[0058] In some embodiments, if the difference between the recorded pH value and the expected pH value is greater than a threshold amount, corrective action may be taken. The threshold amount may be, for example, ±0.03 pH of the expected pH value, ±0.05 pH of the expected pH value, ±0.07 pH of the expected pH value, ±0.09 pH of the expected pH value, ±0.1 pH of the expected pH value, ±0.15 pH of the expected pH value, or ±0.2 pH of the expected pH value. Corrective actions may include, but are not limited to, adjusting the pH meter, adjusting the composition of the mixture, adjusting one or more environmental conditions of the process, or a combination thereof. Adjusting the pH meter may include standardizing the pH meter, recalibrating the pH meter, cleaning, resetting and / or replacing the pH probe, adjusting the reference electrode solution, replacing components of the pH meter, adjusting the position of the pH probe, and / or other measures for changing the signal-to-noise ratio of the pH meter. Adjusting the composition of the mixture may include reformulating any component solution or upstream composition of the mixture, changing process conditions or instrument components of one or more chromatography or separation processes, and / or other measures for changing the material composition of the mixture. Adjusting one or more environmental conditions of the process may include adjusting mixing and / or homogenization processes and systems, adjusting the temperature of the process, adjusting the humidity of the process, adjusting the pressure of the process, or a combination thereof. Such adjustments based on deviations from expected parameters may be incorporated as part of process analytical technology (PAT).

[0059] The above equations and mathematical models can be generated as part of the method for forming an acidic inactivation scheme. The method for forming an acidic inactivation scheme can include making a pool of a mixture (e.g., an eluate), wherein each mixture in the pool contains a target molecule purified during protein affinity capture. For example, a sample pool can be collected from the eluate of a protein affinity chromatography column. The method can also include measuring the pH value and protein concentration (e.g., the concentration of the target molecule) of each sample. After determining the pH value and protein concentration of each sample, each sample can be titrated to determine the amount of acid required to make the sample at the inactivation pH value. In an embodiment, the inactivation pH can be defined as a sufficiently wide range, and two or more repeated titrations can be performed, allowing multiple data points to be collected from each sample in the pool. In other embodiments, only a single data point can be collected from the sample.

[0060] In some embodiments, a regression can be performed between the amount of added acid, the eluate protein concentration, the pH of the mixture, and / or the inactivation pH (e.g., a mathematical model). The relationship can be regressed according to equation 2 or equation 3 as described above. In some embodiments, the method of establishing an acidic inactivation protocol also includes regressing the validation model. The validation model can be regressed according to equation 4 above.

[0061] Figure 1An exemplary process 100 for inactivating viruses in a mixture according to the present disclosure is depicted in the form of a flow chart. According to step 101, a mixture at a first pH value (e.g., greater than 3.9) can be eluted from a chromatography column. According to step 102, the protein concentration (e.g., target molecule concentration) of the mixture can be determined by, for example, UV / visible spectroscopy or other methods. Optionally, the conductivity and / or pH value of the mixture can be determined using, for example, a potentiometric pH meter or other methods. According to step 103, one or more salts can be added to the mixture in an amount sufficient to adjust the conductivity of the mixture. According to step 104, the amount of acid necessary to reduce the pH value of the mixture to a second pH value (e.g., an inactivation pH value) can be calculated. This calculation can be performed based on the protein concentration of the mixture, the pH value of the mixture, or a combination thereof. According to step 105, the first portion of acid can be added to the mixture. In some embodiments, the first portion of acid is a dose of acid equal to the calculated amount of acid added. In other embodiments, the first portion of acid can be 68% to 99% of the volume or amount of acid calculated to add acid. According to step 105, optionally, a secondary acid can be added to the mixture so that the combination of the mixture and the acid is at or below a second pH value (e.g., an inactivation pH value). According to step 106, the combination of the mixture and the acid can be maintained at the second pH value (e.g., an inactivation pH value) for an inactivation period of time, thereby inactivating the virus in the eluate.

[0062] Figure 2An exemplary process 200 for inactivating viruses in a mixture according to the present disclosure is depicted in the form of a flow chart. According to step 201, a mixture containing a target molecule at a first pH value (e.g., greater than or equal to about 5.0 and less than or equal to about 8.5) can be loaded onto a chromatography column. According to step 202, an eluted mixture at a second pH value (e.g., greater than about 3.9 and less than or equal to about 5.0) can be eluted from the chromatography column. According to step 203, the protein concentration (e.g., target molecule concentration) of the eluted mixture is measured and / or recorded by, for example, UV / visible spectroscopy. According to step 204, optionally, the pH value and / or conductivity of the eluted mixture can be measured. The pH value is measured and / or recorded using, for example, a potentiometric acid-base meter (pH meter). According to step 205, one or more salts are added to the mixture in an amount sufficient to adjust the conductivity of the mixture. According to step 206, an acid can be added to the eluted mixture to form a composition of the eluted mixture and the acid, so that the composition exhibits effective virus inactivation. In addition, the composition can have a pH value less than or equal to the second pH value (e.g., less than or equal to about 3.8 and greater than or equal to about 3.0). According to step 207, the expected pH value of the composition can be predetermined using a pH validation model. According to step 208, the pH value of the composition can be measured and / or recorded. According to step 209, the difference between the expected pH value of the composition and the measured / recorded pH value can be calculated. According to step 210, corrective measures can be taken based on the calculated difference between the expected pH value of the composition and the measured and / or recorded pH value.

[0063] Figure 3 An exemplary process 300 for establishing an acidic inactivation scheme according to the present disclosure is depicted in the form of a flow chart. According to step 301, a pool of eluate samples can be made, wherein each eluate sample of the pool of eluate samples contains a target molecule purified during affinity capture. According to step 302, the protein concentration (e.g., target molecule concentration) of each eluate sample of the eluate sample pool can be determined by, for example, ultraviolet / visible spectroscopy. Optionally, the pH value of each eluate sample of the eluate sample pool can be determined by, for example, a potentiometric acid-base meter. According to step 303, by titrating each eluate sample of the eluate sample pool, the amount of acid necessary to reduce the pH value of each eluate sample to the inactivation pH value can be determined. According to step 304, the relationship between the amount of added acid, the eluate protein concentration, the eluate pH value, and / or the inactivation pH value can be regressed. According to step 305, optionally, the confirmation model can also be regressed.

[0064] although Figure 1-Figure 3Each of the figures depicts a specific order of steps, but it should be understood that the steps performed and the order in which the steps are performed can be modified. In addition, steps (e.g., one or more measuring and / or recording steps) can be added, or steps can be removed from any of the methods disclosed herein. In addition, although Figure 1-Figure 3 Each figure depicts the steps associated with the eluate, but it should be understood that the steps are applicable to any mixture containing a target molecule. Example

[0065] The following examples are intended to illustrate the present disclosure and are not limiting in nature. Of course, the present disclosure includes other aspects and embodiments consistent with the foregoing description and the following examples.

[0066] In the following examples, the target polypeptide is prepared from a mixture comprising the target polypeptide, host cell proteins, viruses, and other contaminants, impurities, and components. The target polypeptide is prepared in Chinese hamster ovary cells grown in suspension culture. Example 1

[0067] The target polypeptide was eluted from the protein A affinity column, and multiple samples of the mixture were obtained. The protein concentration of each mixture sample was obtained by UV / visible spectroscopy and is shown in Table 1 below (in grams of protein per liter of mixture). In addition, the pH of each mixture sample was determined and is shown in Table 1.

[0068] The pool of eluate contained forty eluate samples (ie, forty samples of the mixture) and was washed with 0.25 M phosphoric acid (H 3 PO 4 ) solution to an inactivation pH of 3.35 to 3.86 to determine the amount of acid added (e.g., the amount of acid added to bring the mixture to the inactivation pH). For six of the forty samples (Samples 1-6 shown in Table 1), the titrations were performed multiple times to generate multiple data points. For example, 30.89 grams of acid per kilogram of mixture to bring Sample 1 to an inactivation pH of 3.70 is one data point, and 36.24 grams of acid per kilogram of mixture to bring Sample 1 to an inactivation pH of 3.59 when 5.35 grams of additional acid per kilogram of mixture was added is another data point. The data for these titrations are shown in Table 1 below, where the units for the amount of acid added are grams of acid per kilogram of mixture and moles of acid per kilogram of mixture. Table 1: Mixture titration data Example 2

[0069] The titration data shown in Table 1 were used to regress the relationship between the mixture protein concentration, inactivation pH, and the amount of acid added according to Equation 2. The regression equation shown below (Equation 5) was determined to have a coefficient of determination (R) of 0.84. 2 ). w=0.0004532x-0.01135y+0.04213 Equation (5) Example 3

[0070] Still referring to the titration data shown in Table 1, the relationship between the mixture protein concentration, the mixture pH, the inactivation pH, and the amount of acid added was regressed according to Equation 3. It was determined that the regression equation shown below (Equation 6) had a determination coefficient (R) of 0.97. 2 ). Surprisingly, the amount of acid added was highly correlated with the relationship between protein concentration, mixture pH, and inactivation pH as shown in General Equations 2 and 3. w=0.0001986x-0.01162y+0.01510z-0.01692 Equation (6) Example 4

[0071] The titration data shown in Table 1 can also be used to regress the validation model according to General Equation 4. The regression equation shown below (Equation 7) was determined to have a coefficient of determination (R) of 0.93. 2 ). Also unexpectedly, the relationship between the inactivation pH and protein concentration, the mixture pH, and the inactivation pH was highly correlated. y=0.01488x-71.65w+1.094z-0.6727 Equation (7)

[0072] It will be appreciated by those skilled in the art that the concepts upon which the present disclosure is based can be readily used as a basis for designing other methods and systems to achieve the several purposes of the present disclosure. In addition, although various aspects of the present disclosure are described with respect to specific steps in specific processes (e.g., inactivation of viruses in a mixture), it will be appreciated by those skilled in the art that the systems and methods disclosed herein can be applied to other contexts (e.g., inactivation of viruses in other mixtures comprising polypeptides, such as before a chromatography process or after combination of the eluate with other ingredients in the preparation of a formulated drug). Therefore, the claims are not to be considered limited by the foregoing description.

Claims

1. A method for inactivating a virus in a mixture, the method comprising: determining the protein concentration of the mixture; Calculating the amount of acid necessary to lower the pH of the mixture to an inactivation pH based on the protein concentration of the mixture; as well as An amount of acid necessary to bring the pH of the mixture to the inactivation pH is added to the mixture, wherein the pH of the combination of the acid and the mixture is at or below the inactivation pH.

2. The method according to claim 1, further comprising: maintaining the composition at the inactivation pH for an inactivation period of time; as well as After the inactivation period, the composition is titrated to a pH greater than or equal to 4.5 and less than or equal to 8.5, wherein the composition is titrated in less than one hour after the requisite amount of acid is added to the mixture.

3. The method of claim 2, wherein the inactivation time period is from about 20 minutes to about 90 minutes.

4. The method of claim 2, wherein maintaining the composition at the inactivation pH for the inactivation period results in a reduction in viral activity as quantified by a reduction factor greater than or equal to 2.

5.

5. The method of claim 2, wherein maintaining the composition at the inactivation pH for the inactivation period does not adversely affect the adeno-associated virus.

6. The method of claim 2, wherein maintaining the composition at the inactivation pH for the inactivation interval comprises maintaining the composition at a pH greater than or equal to 3.35 during the inactivation interval.

7. The method of claim 1, wherein the amount of acid necessary to lower the pH of the mixture to the deactivation pH is calculated according to the following formula: w=Ex+Fy+Gz+H where x is the protein concentration of the mixture in grams per liter (g / L), y is the inactivation pH, z is the pH of the mixture, w is the amount of acid added in moles of acid per kilogram of mixture, and E, F, G, and H are constants.

8. The method according to claim 7, wherein: E is greater than or equal to 0.0005 L·mol / g·kg and less than or equal to 0.005 L·mol / g·kg; F is greater than or equal to about -0.2 mol / kg and less than or equal to about 0 mol / kg; G is greater than or equal to about 0 mol / kg and less than or equal to about 0.03 mol / kg; and H is greater than or equal to about -0.1 mol / kg and less than or equal to about 0.1 mol / kg.

9. The method according to claim 1, further comprising: using a pH validation model to predetermine an expected pH value of the composition; recording the pH of the composition; and The difference between the expected pH value and the recorded pH value is calculated.

10. The method of claim 9, further comprising taking corrective action if the difference between the expected pH value and the recorded pH value is greater than or equal to about 0.

15.

11. The method according to claim 10, wherein: The corrective action includes adjusting a pH meter, adjusting the composition of the mixture, adjusting one or more environmental conditions, or a combination thereof.

12. A method for inactivating viruses in a mixture, the method comprising: eluting the mixture containing the target molecule from the chromatography device; adding to the mixture a salt in an amount sufficient to adjust the conductivity of the mixture; measuring the protein concentration of the mixture; calculating, based on the protein concentration of the mixture, an amount of acid required to lower the pH of the mixture to an inactivation pH; as well as The desired amount of acid is added to the mixture to form a composition of acid and mixture having a pH at or below the inactivation pH.

13. The method of claim 12, wherein the chromatography device is configured to perform a protein affinity capture process. The method of claim 12 , wherein the mixture comprises an equilibration buffer or a stripping buffer.

15. The method of claim 12, wherein the mixture comprises: Water containing less than 5 vol.% dissolved ions; Alkaline solutions including 0.1N to 1.5N lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide or ammonium hydroxide; or Alcohol solutions include methanol, ethanol, propanol or benzyl alcohol.

16. The method of claim 12, wherein adding the desired amount of acid comprises adding at least 68% of the desired amount of acid in a single addition.

17. A method for establishing an acid inactivation protocol for a mixture, the method comprising: making a pool of eluate samples of the mixture, wherein each eluate sample of the pool of eluate samples contains a target molecule purified in a protein affinity capture process; Determine the pH value and protein concentration of each eluate sample; titrating each eluate sample of the pool of eluate samples to determine the amount of first acid required to bring each eluate sample to a first inactivation pH value, thereby producing an acidified sample pool, wherein the pH value of each acidified sample is equal to or lower than the first inactivation pH value; For each acidified sample in the acidified sample pool, generating a first data point, wherein the first data point includes a first acid amount and a pH value of the acidified sample; For each acidified sample in the acidified sample pool, titrating the acidified sample to determine the amount of second acid required to bring the acidified sample to a second deactivation pH value, thereby generating a deactivated sample pool; For each deactivated sample in the deactivated sample pool, generating a second data point, wherein the second data point includes the amount of the second acid and the pH value of the deactivated sample; and Using the data point and the second data point, the relationship between the protein concentration of the mixture, the pH of the mixture, the inactivation pH range, and the amount of acid required to bring the mixture to the inactivation pH range is regressed.

18. The method of claim 17, further comprising regressing the validation model using the first data point and the second data point.

19. The method of claim 18, wherein the validation model comprises the following equation: y=Kx+Lw+Mz+N Wherein y is the pH of the composition, x is the protein concentration of the mixture in grams per liter, z is the pH of the mixture before the amount of acid is added to the mixture, w is the amount of acid added to the mixture in moles of acid per kilogram of eluate, and K, L, M and N are constants.

20. The method of claim 19, wherein: K is greater than or equal to about 0 L / g and less than or equal to about 0.3 L / g; L is greater than or equal to about -80 kg / mol and less than or equal to about -60 kg / mol; M is greater than or equal to about 0 and less than or equal to about 2.0; and N is greater than or equal to approximately −1.0 and less than or equal to approximately zero.

21. The method of claim 17, wherein the first inactivation p The H value and the second deactivation pH value are less than or equal to about 3.8 and greater than or equal to about 3.0; and The second inactivation pH value is lower than the first inactivation pH value.

Images